Get started
Author

Marko Spasic

Observed name: M Spasic
ORCID: 0009-0005-5693-312X
Observed ORCID: 0009-0005-5693-312X
OpenAlex ID: A5086282906
PD-1 blockade induces responses by inhibiting adaptive immune resistance
2018 · PC Tumeh, CL Harview, et al. · immuneACCESS · 236
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer
2026 · Gregory M. Chen, Ankita Jain, et al. · Nature Biomedical Engineering · 16
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025 · Matthew D. Galsky, Karen A. Autio, et al. · Clinical Cancer Research · 14
PDF
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
2024 · Apostolia M. Tsimberidou, Farah A. Alayli, et al. · The Journal of Experimental Medicine · 12
PDF
Table S8 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2026 · Matthew D. Galsky, Karen A. Autio, et al.
Table S3 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2026 · Matthew D. Galsky, Karen A. Autio, et al.
Table S6 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2026 · Matthew D. Galsky, Karen A. Autio, et al.
Table S2 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2026 · Matthew D. Galsky, Karen A. Autio, et al.
Table S4 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2026 · Matthew D. Galsky, Karen A. Autio, et al.
Table S1 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2026 · Matthew D. Galsky, Karen A. Autio, et al.
Table S9 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2026 · Matthew D. Galsky, Karen A. Autio, et al.
Table S7 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2026 · Matthew D. Galsky, Karen A. Autio, et al.
Table S5 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2026 · Matthew D. Galsky, Karen A. Autio, et al.
Figure S1 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2026 · Matthew D. Galsky, Karen A. Autio, et al.
Data from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025 · Matthew D. Galsky, Karen A. Autio, et al.
Table S3 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025 · Matthew D. Galsky, Karen A. Autio, et al.
PDF
Figure S2 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025 · Matthew D. Galsky, Karen A. Autio, et al.
Table S2 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025 · Matthew D. Galsky, Karen A. Autio, et al.
PDF
Figure S1 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025 · Matthew D. Galsky, Karen A. Autio, et al.
PDF
Table S1 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025 · Matthew D. Galsky, Karen A. Autio, et al.
PDF
Table S4 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025 · Matthew D. Galsky, Karen A. Autio, et al.
PDF
Table S5 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025 · Matthew D. Galsky, Karen A. Autio, et al.
Table S7 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025 · Matthew D. Galsky, Karen A. Autio, et al.
PDF
Table S6 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025 · Matthew D. Galsky, Karen A. Autio, et al.
Table S9 from Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
2025 · Matthew D. Galsky, Karen A. Autio, et al.
PDF
Works count: 26
Citation count: 278
H-index: 4
I10-index: 4
Year
Topic
Type